Vimarsana
Biggest News Aggregation in the World

Page 8 - Cameron Durrant News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cameron Durrant. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cameron Durrant Today - Breaking & Trending Today

Humanigen, Inc.: The Lancet Respiratory Medicine Publishes Peer-Reviewed Paper and Independent Expert Commentary on Positive Phase 3 Lenzilumab Results - Vimarsana News

Humanigen, Inc.: The Lancet Respiratory Medicine Publishes Peer-Reviewed Paper and Independent Expert Commentary on Positive Phase 3 Lenzilumab Results

Lenzilumab is a variant-agnostic therapeutic that targets the dysregulated host immune response, an approach which may be of greater value than targeting the virus in hospitalized patients1 Per

Humanigen, Inc.: European Commission Selects Humanigen's Lenzilumab as One of the 10 Most Promising Treatments for COVID-19 - Vimarsana News

Humanigen, Inc.: European Commission Selects Humanigen's Lenzilumab as One of the 10 Most Promising Treatments for COVID-19

Ten most promising treatments for COVID-19 identified by the European Commission's independent experts as having "the highest potential impact on the pandemic" European Commission's independent

European Commission Selects Humanigen's Lenzilumab as One of the 10 Most Promising Treatments for COVID-19 - Vimarsana News

European Commission Selects Humanigen's Lenzilumab as One of the 10 Most Promising Treatments for COVID-19

Press release content from Business Wire. The AP news staff was not involved in its creation.

Source: apnews.com
Humanigen, Inc.: European Commission Selects Humanigen's Lenzilumab as One of the 10 Most Promising Treatments for COVID-19 - Vimarsana News

Humanigen, Inc.: European Commission Selects Humanigen's Lenzilumab as One of the 10 Most Promising Treatments for COVID-19

Ten most promising treatments for COVID-19 identified by the European Commission's independent experts as having "the highest potential impact on the pandemic" European Commission's independent

Humanigen, Inc.: Humanigen announces preparation of Phase 1b study of ifabotuzumab in solid tumors following presentation of Phase 1 study results at EANM'21 - Vimarsana News

Humanigen, Inc.: Humanigen announces preparation of Phase 1b study of ifabotuzumab in solid tumors following presentation of Phase 1 study results at EANM'21

An abstract showing tumor specific targeting at all known tumor sites in glioblastoma patients, with no normal tissue uptake of ifabotuzumab, from a Phase 1 study will be presented at EANM'21